A rating of 3 would signify a consensus Hold recommendation. Investors who are keeping close eye on Mylan N.V. …
Abbott Laboratories (NYSE: ABT) has agreed to sell its non-U.S. generic drug business to Mylan Inc. (NASDAQ: MYL) in an all-stock transaction valued at $5.3 billion. Mylan will form a new company based in the Netherlands, of which …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
This quick video takes a look at Mylan (MYL) ahead of its earnings report. The pharma company has been under pressure for much of 2016 while a bottom 33% industry rank isn’t helping matters either. Even more troubling than the weak …
The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects. Generic drugs company Mylan has announced its intention of delisting from the Tel Aviv Stock Exchange. Mylan has been traded in Tel Aviv …
This week is almost all about the presidential election, which will resound throughout the stock market -- especially if Donald Trump is elected. Far more studies than not say the markets will tank if Trump surprises most pundits and …
SmarTrend identified an Uptrend for Mylan Nv (NASDAQ:MYL) on September 12th, 2017 at $33.44. In approximately 4 months, Mylan Nv has returned 40.10% as of today's recent price of $46.85. In the past 52 weeks, shares of Mylan Nv …
On Monday, shares of controversy-ridden pharmaceutical company Mylan NV (MYL) are gaining, up over 8.5% in morning trading after the drug maker agreed to pay $465 million in order to settle charges that Mylan overcharged the U.S. …